Basic Information
Apidra
Regulatory Information
EMEA/H/C/000557
September 27, 2004
June 3, 2004
34
August 9, 2024
Company Information
Germany
Sanofi-Aventis Deutschland GmbH Brueningstrasse 50, D-65926 Frankfurt am Main
Sanofi-Aventis Deutschland Gmbh
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of adults, adolescents and children, six years or older with diabetes mellitus, where treatment with insulin is required.
Overview Summary
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).